Working together towards drug security
SAUDIBIO is a Joint Stock company duly incorporated in the Kingdom of Saudi Arabia. It is the owner of The First and Only multipurpose sterile fill and finish facility for biopharmaceutical products including Recombinant Human Insulin and Biosimilars products in Saudi Arabia.
SAUDIBIO was founded by DR.KHALED ALMOSA, Health Care Management Consultant. Dr.Khaled is a member of KSA supreme committee for Research, Development & Innovation, Council of Economics & Development Affairs, Council of Ministers. SAUDIBIO is chaired by H.E.Dr.Hussein Aljezairy, Ex-Minister of health, Saudi Arabia and Ex-Regional director for the Eastern Mediterranean Region, World Health Organization.
As industry leaders, we are focused on a new era of development and growth powered by the Vision 2030 of Saudi Arabia
Insight into how it works when partnering with us
SAUDIBIO is committed to participate with government strategy towards drug security by making essential drugs locally available.
Localizing - Many new local regulations were issued to support and favor local products in all governmental tenders.
SAUDIBIO is the First & Only GMP certified biotech manufacturing facility in the Kingdom of Saudi Arabia
Our capabilities in the region - beyond manufacturing- include registration of products at regulatory authorities and generating ethical sales across MENA.
Our Business Partners
Strength through our unique diversity
NOVO NORDISK is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
NOVO NORDISK and SAUDIBIO have signed license, supply and quality agreements for local manufacturing of Insulin and Haemophilia products.
SANDOZ is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group.
SANDOZ & SAUDIBIO have signed localization agreement for selected biosimilars products.
GLENMARK is a leading integrated research-based, global pharmaceutical company and it is the first company in India has received approval from DCGI to manufacture & market an oral antiviral drug Fabiflu (Favipiravir) for use in mild to moderate COVID-19 .
GLENMARK and SAUDIBIO have signed license, supply and quality agreements of selected branded generics including favipiravir.
H.E Saudi Minister of Industry & Mineral resources launches the first Insulin batch (SaudiBio - Novo Nordisk)
Benefiting the community - locally and globally
We adopt the highest quality standards to deliver reliable service & high-quality products from the GMP Certified production facility.
We care for the community we live and work in.